Related Experiment Video

Updated: Oct 13, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Increased platelet activation and endothelial dysfunction in patients with atrial fibrillation immediately following

I R Goldsmith1, L S Foo, A D Blann

  • 1Haemostasis, Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, England.

Clinical Cardiology
|August 15, 2000
PubMed

Insights

Percutaneous balloon mitral valvuloplasty (PBMVP) increases risk of blood clots due to heightened platelet activation and endothelial dysfunction. These changes post-PBMVP suggest a need for antithrombotic therapy to prevent thromboembolism.

Area of Science:

  • Cardiology
  • Hematology
  • Vascular Biology

Background:

  • Percutaneous balloon mitral valvuloplasty (PBMVP) is associated with a 3% risk of systemic thromboembolism.
  • Hypercoagulability, indicated by abnormal coagulation, platelet activation, and endothelial dysfunction, is hypothesized to contribute to this risk.

Purpose of the Study:

  • To investigate indices of platelet activation, endothelial dysfunction, and coagulation in patients undergoing PBMVP.
  • To compare these markers in patients with mitral stenosis and chronic atrial fibrillation against healthy controls.

Main Methods:

  • Measured soluble P-selectin (sPsel) for platelet activation, von Willebrand factor (vWf) for endothelial dysfunction, and fibrinogen for coagulation.
  • Collected peripheral venous and arterial blood samples from 16 patients before and after PBMVP, and from 16 healthy controls.

Main Results:

  • Patients exhibited higher baseline vWf and fibrinogen levels compared to controls, indicating baseline endothelial dysfunction and hypercoagulability.
  • Post-PBMVP, significant increases in venous and arterial soluble P-selectin (sPsel) were observed, indicating increased platelet activation.
  • Venous von Willebrand factor (vWf) levels increased 24 hours post-PBMVP, further supporting increased endothelial dysfunction.

Conclusions:

  • Patients with mitral stenosis and chronic atrial fibrillation show baseline endothelial dysfunction and hypercoagulability.
  • PBMVP induces platelet activation and endothelial dysfunction, potentially increasing thromboembolism risk.
  • Findings suggest the necessity of adequate antithrombotic therapy following PBMVP.
Abstract

Related Concept Videos

Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Mitral Valve Prolapse II: Assessment and Management01:22

Mitral Valve Prolapse II: Assessment and Management

IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular tachycardia.
Mitral Valve Prolapse I: Introduction01:27

Mitral Valve Prolapse I: Introduction

IntroductionThe mitral valve, one of the heart's four valves, regulates blood flow. These valves have flaps that open and close to direct blood properly through the heart and body. During each heartbeat, the flaps open for blood to pass through and seal shut to prevent backflow. Specifically, the mitral valve opens to allow blood flow from the heart's upper left chamber to the lower left chamber. It then closes securely as the lower left chamber contracts to pump blood to the body, preventing...
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.